Navigation Links
Corgenix Reports Third Quarter Fiscal 2008 Financial Results
Date:5/15/2008

Total revenues for the quarter decrease approximately 3% vs. prior year

DENVER, May 15 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-QSB and reported financial results. The report disclosed that the company's sales and operating results have advanced during the quarter and nine months ended March 31, 2008, and further confirmed that the initiatives the company put in place several months earlier are continuing to prove effective. Some of the results highlighted by the report are as follows:

-- Total revenues for the quarter decreased $61,166 or 3.1% vs. the prior

year's comparable quarter.

-- Revenues, excluding contract manufacturing, increased $186,686 or 10.6%

vs. the prior year's comparable quarter.

-- Total operating expenses decreased $30,009 or 2.4% vs. the prior year's

comparable quarter.

-- Operating loss for the quarter was $62,912 vs. an operating loss of

$37,423 in the prior year's comparable quarter.

-- Net loss for the quarter was $352,102 vs. $329,370 in the prior year's

comparable quarter.

"While much was accomplished in the quarter, including product sales growth and reduction in operating expenses, the overall financial results in the third quarter were less than we had expected, reflecting to some extent, the timing of our sales orders, but to a greater extent, softer sales in the contract manufacturing aspect of our business, which was a direct result of the new business strategy of our largest contract manufacturing customer," said Douglass Simpson, President and CEO of Corgenix. "Excluding contract manufacturing, our sales increased 10.6% over the same period in the prior year. It's important to recognize that Corgenix is still growing well ahead of industry averages -- our sales are up almost 20% for the nine months year-to-date even with the third quarter decline in contract manufacturing."

Mr. Simpson continued, "The initiatives which we implemented beginning in the final quarter of fiscal 2007 to increase sales and decrease operating expenses continue to move the Company in a positive direction. We are still committed to doing what is necessary to achieve our financial goals including maintaining the initiatives to reduce our operating expenses, improve our customer and sales experience and continue to lay the groundwork to accelerate future revenue and earnings growth."

Regarding the hurdles faced in establishing markets for our new products, Mr. Simpson stated, "We are continuing to put forth a significant effort worldwide to build a solid and sustainable foundation for our AspirinWorks(R) product and we are seeing results of those efforts. Even though we have seen a number of studies on the importance of aspirin effectiveness testing published in the last year, and further expect there will be several more over the next 12-18 months, it is clear that the development of this market will take longer than we had originally anticipated. Our experience is that this is typical when bringing cutting-edge products into the market. Current fiscal year sales of AspirinWorks, although not yet material, will be greater than first-year sales of any of our other 52 Corgenix products, but will still be lower than we had originally expected. We believe that our efforts today will bear fruit in the years to come as this market further develops. AspirinWorks is now available worldwide."

The Company also indicated that it expects total fourth quarter sales to be approximately the same as or slightly lower than sales in the third quarter, which would still result in another record year for revenues.

Third Quarter 2008 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of third quarter results to join a shareholders conference call on Thursday, May 15, 2008 at 4:00 PM EDT (2:00 PM MDT). Interested parties can join the call by dialing 800-894-5910. International participants may access the call by dialing 1 785-424-1052. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 723-0394 for domestic participants and 1 402-220 2649 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

SUMMARY OF FINANCIAL HIGHLIGHTS

($000 of U.S. dollars except shares outstanding and per share amounts)

CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES

OPERATIONAL DATA

Three Months Ended Nine Months Ended

March 31, March 31, March 31, March 31,

2008 2007 2008 2007

(unaudited) (unaudited) (unaudited) (unaudited)

Net sales $1,951 $2,012 $6,455 $5,391

Gross profit 1,140 1,196 3,627 2,134

Total operating expenses 1,203 1,233 3,464 3,998

Operating income (loss) (63) (37) 163 (740)

Net loss (352) (329) (1,101) (2,081)

Basic and diluted loss

per share $(0.01) $(0.03) $(0.05) $(0.17)

Weighted average shares

outstanding 26,462,150 13,079,649 23,601,550 12,047,554

SUMMARY BALANCE SHEET DATA

(in thousands)

March 31, 2008 June 30, 2007

(unaudited) (audited)

Cash $1,652 $1,324

Working capital 3,254 2,070

Total assets 8,657 8,889

Long-term debt 1,469 $2,508

Total stockholders' equity 4,401 2,993


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Cardiogenesis Reports First Quarter 2008 Results
4. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
5. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
6. The Female Health Company Reports 267% Increase in Second Quarter Earnings
7. NicOx Reports First Quarter 2008 Financial Results
8. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
9. IRIDEX Reports First Quarter 2008 Financial Results
10. Cardiome Reports First Quarter Results
11. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology: